Navigation Links
Trovagene Announces Commercial Launch Timelines for HPV Carrier and Oncogene Mutation Tests
Date:2/12/2013

SAN DIEGO, Feb. 12, 2013 /PRNewswire/ -- Trovagene, Inc. (NASDAQ:  TROV) today announced that the development of its proprietary, urine-based HPV carrier screening test is progressing well and the Company expects to achieve analytical and clinical validation of the test in its CLIA laboratory in March 2013. When validation is completed, the test will be available to clinicians and their patients. In addition to the ongoing HPV validation studies, one clinical trial has been completed in India and two additional trials are underway in collaboration with the Barretos Cancer Center, Brazil and Strand Life Sciences, India.

(Logo: http://photos.prnewswire.com/prnh/20120620/LA28014LOGO)

The Company has extended its planned offering of urine-based oncogene mutation tests for 2013 to include a test for the detection of a specific p53 mutation and a specific double mutation in the hepatitis B virus (HBV). Both markers are strongly associated with hepatocellular carcinoma (HCC), which is the third leading cause of cancer mortality worldwide. Availability of the HCC test is anticipated in the fourth quarter of 2013. Trovagene's KRAS oncogene mutation test is expected to be introduced in the second quarter 2013. In support of the Company's BRAF oncogene mutation test, a clinical trial with MD Anderson focused on mutations in patients with advanced or metastatic cancers is ongoing. It is anticipated that sufficient clinical specimens will be obtained to support a third quarter offering of this test. Additional clinical studies, including a trial to evaluate the detection of PIK3CA oncogene mutations, are in preparation.

On February 13, 2013, at 9 a.m. ET, Trovagene will present at the Leerink Swan Global Healthcare Conference hosted at the Waldor
'/>"/>

SOURCE Trovagene, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Trovagene to Introduce First Urine-Based Molecular Diagnostic Test for Transrenal Cancer Mutation Monitoring
2. Trovagene and Barretos Cancer Hospital, Brazil, to Evaluate Urine-Based HPV Assay as Potential Pap Smear Replacement
3. Trovagene Announces Closing of Private Placement of $3.76 Million from the Sale of Restricted Common Stock and Warrants
4. Dr. Paul Billings joins Trovagenes Scientific Advisory Board
5. Trovagene, Inc., Announces Third Quarter and Year to Date Earnings, Provides Milestone Update
6. Trovagene and Strand Life Sciences Agree to Validate and Commercialize Urine-Based HPV Test in India and South Asia
7. Trovagene, Inc. Announces Second Quarter and Year to Date Earnings, Provides Milestone Update
8. Trovagene, Inc., Announces Issuance of U.S. Patent for NPM Mutants to Diagnose and Monitor Acute Myeloid Leukemia
9. Trovagene to Study Trans-Renal KRAS Mutation Detection in Pancreatic Cancer
10. Trovagene Announces Plans to Develop Proprietary Test for High Risk HPV Carrier Screening from Urine
11. Keith McCormick Joins Trovagene, Inc. as Head of Commercial Operations
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/1/2014)... 2014  Dyadic International, Inc. ("Dyadic") (OTCQX: DYAI), ... technology used to develop and produce enzymes and ... and industrial enzymes industries, today announced the receipt ... for commercial scale production of Abengoa,s proprietary cellulase ... under Abengoa,s license agreement with Dyadic. ...
(Date:10/1/2014)... 2014 NeuroCall, Inc., ("NeuroCall") announced today that ... and Teleneurology services. Dr. Ricardo Garcia-Rivera , Founder ... extremely proud that our quality of service has been ... provide lifesaving support and continuity of care to patients ... the United States ." ...
(Date:10/1/2014)... LOUIS , Oct. 1, 2014  Express Scripts ... two nationally available 2015 Express Scripts Medicare ® ... pharmacy network featuring Walgreens (NYSE: WAG ) ... more value, choice and clinical support  for their Medicare ... Express Scripts Medicare Value or Choice ...
Breaking Medicine Technology:Dyadic International Reports Licensing Payment For Commercial-Scale Production Of C1-Based Cellulase Enzymes 2Dyadic International Reports Licensing Payment For Commercial-Scale Production Of C1-Based Cellulase Enzymes 3NeuroCall Awarded Joint Commission Accreditation 2Express Scripts Collaborates with Walgreens to Create Value-Driven Medicare Prescription Drug Plan Pharmacy Network 2Express Scripts Collaborates with Walgreens to Create Value-Driven Medicare Prescription Drug Plan Pharmacy Network 3Express Scripts Collaborates with Walgreens to Create Value-Driven Medicare Prescription Drug Plan Pharmacy Network 4
... -- LEUVEN, Belgium, September 6, 2010 ... ... ... are keyed by longUrl, so we need to grab the first one. for (var r in data.results) ...
... O R R E C T I O N - Mindray Medical... -- SHENZHEN, China, Aug. 25 /PRNewswire-Asia-FirstCall/ ... ... if (typeof(lpUnit)==,undefined,) var lpUnit=,PRN,; --> ... function(data) { var s = ,; var first_result; // Results are keyed by longUrl, so we need to ...
Cached Medicine Technology:ThromboGenics Presents Positive Pooled Results from the MIVI-TRUST Phase III Program, Confirming Microplasmin's Potential to Transform the Treatment of Retinal Disorders 2ThromboGenics Presents Positive Pooled Results from the MIVI-TRUST Phase III Program, Confirming Microplasmin's Potential to Transform the Treatment of Retinal Disorders 3ThromboGenics Presents Positive Pooled Results from the MIVI-TRUST Phase III Program, Confirming Microplasmin's Potential to Transform the Treatment of Retinal Disorders 4ThromboGenics Presents Positive Pooled Results from the MIVI-TRUST Phase III Program, Confirming Microplasmin's Potential to Transform the Treatment of Retinal Disorders 5ThromboGenics Presents Positive Pooled Results from the MIVI-TRUST Phase III Program, Confirming Microplasmin's Potential to Transform the Treatment of Retinal Disorders 6ThromboGenics Presents Positive Pooled Results from the MIVI-TRUST Phase III Program, Confirming Microplasmin's Potential to Transform the Treatment of Retinal Disorders 7ThromboGenics Presents Positive Pooled Results from the MIVI-TRUST Phase III Program, Confirming Microplasmin's Potential to Transform the Treatment of Retinal Disorders 8ThromboGenics Presents Positive Pooled Results from the MIVI-TRUST Phase III Program, Confirming Microplasmin's Potential to Transform the Treatment of Retinal Disorders 9ThromboGenics Presents Positive Pooled Results from the MIVI-TRUST Phase III Program, Confirming Microplasmin's Potential to Transform the Treatment of Retinal Disorders 10/C O R R E C T I O N - Mindray Medical International Limited / 2/C O R R E C T I O N - Mindray Medical International Limited / 3/C O R R E C T I O N - Mindray Medical International Limited / 4/C O R R E C T I O N - Mindray Medical International Limited / 5/C O R R E C T I O N - Mindray Medical International Limited / 6/C O R R E C T I O N - Mindray Medical International Limited / 7
(Date:10/1/2014)... protein beta-amyloid is strongly associated with Alzheimer,s disease; however, ... peptide is the causal agent of the onset and ... confirmation is that beta-amyloid is not harmful when found ... when it self-assembles to form the so-called amyloid fibrils ... beta-amyloid alone, but with multiple ones because each aggregate ...
(Date:10/1/2014)... new research study published today in the Journal ... patients older than 50 years with moderate or severe ... , Researchers from the University of Melbourne randomly assigned ... pain to no acupuncture or sham or pretend laser ... with participants and acupuncturists blinded to laser and sham ...
(Date:10/1/2014)... Physical Sciences Research Council (EPSRC) will focus on ... systems which run, for example, manufacturing plants, power ... , The research will help understand and ... systems behind our critical national infrastructure. , ... (RITICS), based at Imperial College London, is co-ordinating ...
(Date:10/1/2014)... BOSTON (October 1, 2014) Despite a policy ... with developmental disabilities, this vulnerable population continues to ... of The Journal of the American Dental ... Medicine and Tufts University School of Dental Medicine ... factors influencing at-home oral care provided by caregivers ...
(Date:10/1/2014)... 2014 Familylifeinsurancequotes.org has released a ... for senior citizens. , Senior citizens can qualify ... sell coverage to seniors who are over 50 years ... without taking a medical examination. , Term life insurance ... senior clients can qualify. Having life insurance during retirement ...
Breaking Medicine News(10 mins):Health News:Laying siege to beta-amyloid, the key protein in Alzheimer's disease 2Health News:Study finds acupuncture does not improve chronic knee pain 2Health News:£2.5 million to recognize and reduce cyber-attack threats to critical infrastructure 2Health News:To improve oral health of adults with developmental disabilities, support caregivers 2Health News:To improve oral health of adults with developmental disabilities, support caregivers 3Health News:Affordable Term Life Insurance - Senior Citizens Can Qualify for Coverage! 2
... an Army leader and a military surgeon are among the ... the Henry M. Jackson Foundation for the Advancement of Military ... which will take place at the National Museum of Women ... by service members, veterans and civilians who are working together ...
... News) -- Prenatal diagnosis, early surgery and well-coordinated care by ... cleft lip and/or cleft palate, experts say. Cleft lip ... pregnancy when the roof of the mouth fails to fuse ... United States each year and is the second most common ...
... Tierney, M.D., president and CEO of the Regenstrief Institute ... Indiana University School of Medicine, received a 2011 Distinguished ... and Education Meeting on April 28 in Washington, DC. ... Achievement and Contribution to Clinical and Translational Science. He ...
... A gene known to be important in cardiac development ... result in obstruction of the left ventricular outflow tract. ... Nationwide Children,s Hospital and appearing in the journal ... outflow tract (LVOT) malformations, including aortic valve stenosis, coarctation ...
... Australia and Europe. Large resources are set aside for research ... the research field is still new but researchers from ... years ago the Norwegian health care system had a low ... sectors", says Professor Karina Aase at the University of Stavanger. ...
... in powerful positions are just as likely as men to cheat ... that men are more likely than women to cheat on their ... gender, according to the study published April 28 in the journal ... research in the past that indicates that gender is the strongest ...
Cached Medicine News:Health News:Dinner to honor icons of military medicine 2Health News:Early Surgery Boosts Outcomes for Babies With Cleft Palate 2Health News:Tierney named 2011 Clinical and Translational Research Distinguished Investigator 2Health News:Study identifies second gene associated with specific congenital heart defects 2Health News:Sustaining vulnerable lives 2Health News:Sustaining vulnerable lives 3Health News:Powerful Women as Likely to Cheat as Men, Study Finds 2
Double ended 1.75 mm by 30 mm sterling silver blade. Flat serrated handle with polished finish....
4 mm wide by 17.5 mm flat platinum spatula on 34 mm shaft. Flat serrated handle with polished finish. Most popular size or model....
... Duckbilled spatula designed to enter ... broad enough to efficiently manipulate the ... Spatula is useful for rotating and ... rounded tip with notch and curved ...
Double ended lasik spatula with flattened tip for lifting and smoothing the corneal flap. The sharp tip is useful to outline a previous flap in preparation for retreatment....
Medicine Products: